|
|
|
|
|
|
|
03.09.26 - 23:24
|
Samsara Posts Q2 Profit As Revenue Rises 30% (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Samsara Inc. (IOT) on Thursday reported second-quarter net income of $16.2 million, or $0.03 per share, compared to a net loss of $16.8 million, or $0.03 per share, last yea......
|
|
|
|
|
|
|
|
|
|
|
03.09.26 - 22:15
|
Samsara Reports Second Quarter Fiscal Year 2027 Financial Results (Business Wire)
|
|
|
Q2 revenue of $508.4 million, representing 30% year-over-year growth and 29% in constant currency
Q2 net new ARR of $134.1 million, representing 28% year-over-year growth in both actual and constant currency
Ending ARR of $2.125 billion, representing 30% year-over-year growth
Customers with ARR over $1,000,000 generated over $500 million of ARR, representing over 50% year-over-year growth for the third consecutive quarter
GAAP earnings per share of $0.03, representing the fourth consecutive quarter of GAAP profitability
SAN FRANCISCO--(BUSINESS WIRE)--Samsara Inc. (NYSE: IOT), the pioneer of the Connected Operations® Platform, today reported financial results for the second quarter ended August 1, 2026, and released a shareholder letter accessible from the Samsara investor relations website at investors.samsara.com.
“Samsara delivered another quarter of durable and efficient growth, crossing $2.1 billion in ARR with 30% year-over-year growth for the third consecutive quarter,” said Sanjit Biswas, CEO...
|
|
|
|
|
|
|
01.09.26 - 14:03
|
Samsara Vision Promotes Jason Herod to President and Chief Executive Officer (Business Wire)
|
|
|
FAR HILLS, N.J.--(BUSINESS WIRE)--#AMD--Samsara Vision, a company focused on bringing vision and freedom back to patients with late-stage, age-related macular degeneration (AMD) through advanced visual prosthetic devices, today announced the promotion of Jason Herod to President and Chief Executive Officer, effective April 28, 2026. Having joined Samsara Vision in 2021, Mr. Herod was most recently Chief Commercial Officer, responsible for executing the commercialization of the company's flagship product, the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®) for late-stage AMD.
With more than 29 years of ophthalmic medical device, pharmaceutical, and OTC business experience, Mr. Herod joined Samsara Vision after 15 years with Alcon, where he was most recently the Global Senior Director, Presbyopia Correcting IOLs, Surgical. Prior to that, he held many commercial and marketing roles of increasing responsibility in General Management, country, regional and global marketing, and as...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
